Light
Dark
System
Log In
Loading...
Compare / EASA/
Incorporated Amendments
/
Compare & Highlight Differences
AMC2 MED.B.025 Metabolic and endocrine systems
Available versions for ERULES-1963177438-11224
ED Decision 2019/002/R
found in: Aircrew (1178/2011) Part-FCL Part-MED Part-CC Part-ARA Part-ORA Part-DTO (Dec 2024)
From
Aircrew (1178/2011... (Nov 2025)
Aircrew (1178/2011... (Dec 2024)
Aircrew (1178/2011... (Aug 2023)
From section
To
Aircrew (1178/2011... (Nov 2025)
Aircrew (1178/2011... (Dec 2024)
Aircrew (1178/2011... (Aug 2023)
To section
No visible text changes
0 removals
0 additions
View
Rich
Plain
Sync scrolling
Share
From
Show details
Hide details
To
Show details
Hide details
Version
Show side by side
AMC2 MED.B.025 Metabolic and endocrine systems ED Decision 2019/002/R (a) Metabolic, nutritional or endocrine dysfunction Applicants with metabolic, nutritional or endocrine dysfunction should be assessed as unfit. A fit assessment may be considered if the condition is asymptomatic, clinically compensated and stable. (b) Obesity Applicants with a Body Mass Index ³ 35 may be assessed as fit only if the excess weight is not likely to interfere with the safe exercise of the applicable licence(s) and the results of a risk assessment, including evaluation of the cardiovascular system and evaluation of the possibility of sleep apnoea, are satisfactory. (c) Addison’s disease Applicants with Addison’s disease may be assessed as fit provided that cortisone is carried and available for use whilst exercising the privileges of the applicable licence(s). (d) Gout Applicants with acute gout should be assessed as unfit until asymptomatic. (e) Thyroid dysfunction Applicants with thyroid disease may be assessed as fit once a stable euthyroid state is attained. (f) Abnormal glucose metabolism Glycosuria and abnormal blood glucose levels require investigation. A fit assessment may be considered if normal glucose tolerance is demonstrated (low renal threshold) or impaired glucose tolerance is fully controlled by diet and regularly reviewed. (g) Diabetes mellitus Applicants with diabetes mellitus may be assessed as fit. The use of antidiabetic medications that are not likely to cause hypoglycaemia may be acceptable.
AMC2 MED.B.025 Metabolic and endocrine systems ED Decision 2019/002/R (a) Metabolic, nutritional or endocrine dysfunction Applicants with metabolic, nutritional or endocrine dysfunction should be assessed as unfit. A fit assessment may be considered if the condition is asymptomatic, clinically compensated and stable. (b) Obesity Applicants with a Body Mass Index ³ 35 may be assessed as fit only if the excess weight is not likely to interfere with the safe exercise of the applicable licence(s) and the results of a risk assessment, including evaluation of the cardiovascular system and evaluation of the possibility of sleep apnoea, are satisfactory. (c) Addison’s disease Applicants with Addison’s disease may be assessed as fit provided that cortisone is carried and available for use whilst exercising the privileges of the applicable licence(s). (d) Gout Applicants with acute gout should be assessed as unfit until asymptomatic. (e) Thyroid dysfunction Applicants with thyroid disease may be assessed as fit once a stable euthyroid state is attained. (f) Abnormal glucose metabolism Glycosuria and abnormal blood glucose levels require investigation. A fit assessment may be considered if normal glucose tolerance is demonstrated (low renal threshold) or impaired glucose tolerance is fully controlled by diet and regularly reviewed. (g) Diabetes mellitus Applicants with diabetes mellitus may be assessed as fit. The use of antidiabetic medications that are not likely to cause hypoglycaemia may be acceptable.
##### AMC2 MED.B.025 Metabolic and endocrine systems *ED Decision 2019/002/R* (a) Metabolic, nutritional or endocrine dysfunction Applicants with metabolic, nutritional or endocrine dysfunction should be assessed as unfit. A fit assessment may be considered if the condition is asymptomatic, clinically compensated and stable. (b) Obesity Applicants with a Body Mass Index ³ 35 may be assessed as fit only if the excess weight is not likely to interfere with the safe exercise of the applicable licence(s) and the results of a risk assessment, including evaluation of the cardiovascular system and evaluation of the possibility of sleep apnoea, are satisfactory. (c) Addison’s disease Applicants with Addison’s disease may be assessed as fit provided that cortisone is carried and available for use whilst exercising the privileges of the applicable licence(s). (d) Gout Applicants with acute gout should be assessed as unfit until asymptomatic. (e) Thyroid dysfunction Applicants with thyroid disease may be assessed as fit once a stable euthyroid state is attained. (f) Abnormal glucose metabolism Glycosuria and abnormal blood glucose levels require investigation. A fit assessment may be considered if normal glucose tolerance is demonstrated (low renal threshold) or impaired glucose tolerance is fully controlled by diet and regularly reviewed. (g) Diabetes mellitus Applicants with diabetes mellitus may be assessed as fit. The use of antidiabetic medications that are not likely to cause hypoglycaemia may be acceptable.